ANAB (STOCKS)
AnaptysBio, Inc. Common Stock
$56.020000
-0.960000 (-1.68%)
Prev close: $56.980000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Daniel R. Faga
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,760.98M
- Employees
- 136
- P/E (TTM)
- -52.74
- P/B (TTM)
- 129.77
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.84 | $-0.62 | -1.2241 | -198.75% |
|
Dec 2025 (Q4)
|
$1.58 | $0.96 | +0.6227 | +65.05% |
|
Sep 2025 (Q3)
|
$0.52 | $-1.47 | +1.9881 | +135.42% |
|
Jun 2025 (Q2)
|
$-1.34 | $-1.57 | +0.2325 | +14.79% |
Financial Statements
| Revenues | $232.39M |
| Benefits Costs and Expenses | $259.02M |
| Costs And Expenses | $259.02M |
| Nonoperating Income/Loss | -$67.43M |
| Operating Expenses | $191.59M |
| Operating Income/Loss | $40.80M |
| Income/Loss From Continuing Operations After Tax | -$26.79M |
| Income/Loss From Continuing Operations Before Tax | -$26.63M |
| Income Tax Expense/Benefit | $160.00K |
| Net Income/Loss | -$26.79M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$26.79M |
| Net Income/Loss Available To Common Stockholders, Basic | -$26.79M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.94 |
| Diluted Earnings Per Share | -$0.96 |
| Basic Average Shares | 85,007,000 |
| Diluted Average Shares | 86,192,000 |
| Assets | $329.68M |
| Current Assets | $316.11M |
| Accounts Receivable | $25.75M |
| Other Current Assets | $290.36M |
| Noncurrent Assets | $13.58M |
| Fixed Assets | $1.28M |
| Other Non-current Assets | $12.30M |
| Liabilities | $316.94M |
| Current Liabilities | $41.70M |
| Accounts Payable | $7.52M |
| Wages | $5.53M |
| Other Current Liabilities | $28.65M |
| Noncurrent Liabilities | $275.24M |
| Equity | $12.75M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $12.75M |
| Liabilities And Equity | $329.68M |
| Net Cash Flow From Operating Activities | $4.48M |
| Net Cash Flow From Operating Activities, Continuing | $4.48M |
| Net Cash Flow From Investing Activities | $248.17M |
| Net Cash Flow From Investing Activities, Continuing | $248.17M |
| Net Cash Flow From Financing Activities | -$102.81M |
| Net Cash Flow From Financing Activities, Continuing | -$102.81M |
| Net Cash Flow | $149.83M |
| Net Cash Flow, Continuing | $149.83M |
| Comprehensive Income/Loss | -$26.93M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$27.09M |
| Other Comprehensive Income/Loss | $11.70M |
| Other Comprehensive Income/Loss Attributable To Parent | -$307.00K |